Understanding how cells manufacture dolichol—a lipid essential for protein modification—could unlock new therapeutic approaches for rare genetic disorders affecting thousands of children worldwide. These congenital disorders of glycosylation impair how proteins receive their crucial sugar attachments, leading to developmental delays and organ dysfunction. The discovery that dolichol production follows a previously unknown three-step biochemical route rather than a single conversion challenges a fundamental assumption in cell biology. Budding yeast research has revealed that the DFG10 gene, along with its human counterpart SRD5A3, orchestrates this complex pathway where polyprenol undergoes multiple enzymatic modifications before becoming functional dolichol. This multi-step process involves specific intermediate compounds and requires precise coordination between cellular compartments, suggesting far greater complexity than the direct conversion model that has guided research for years. The evolutionary conservation of this pathway from yeast to humans indicates its fundamental importance for cellular function and suggests that therapeutic interventions targeting individual steps could offer more precise treatment options. Current treatments for glycosylation disorders remain largely supportive, but mapping this detailed biochemical pathway opens possibilities for enzyme replacement therapies or small molecule interventions. The finding that cells have maintained this elaborate three-step system throughout evolution, rather than streamlining to a simpler process, hints at regulatory advantages that researchers are only beginning to understand. For families affected by CDGs, this mechanistic clarity represents a crucial step toward developing targeted therapies that could address the root cause rather than merely managing symptoms.